239 related articles for article (PubMed ID: 31626050)
21. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.
Adigweme I; Futa A; Saidy-Jah E; Edem B; Akpalu E; Dibbasey T; Sethna V; Dhere R; Kampmann B; Bengt C; Sirr J; Hosken N; Goldblatt D; Antony K; Alderson MR; Lamola S; Clarke E
Lancet Infect Dis; 2023 May; 23(5):609-620. PubMed ID: 36638819
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.
Snape MD; Klinger CL; Daniels ED; John TM; Layton H; Rollinson L; Pestridge S; Dymond S; Galiza E; Tansey S; Scott DA; Baker SA; Jones TR; Yu LM; Gruber WC; Emini EA; Faust SN; Finn A; Heath PT; Pollard AJ
Pediatr Infect Dis J; 2010 Dec; 29(12):e80-90. PubMed ID: 21155091
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
26. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States.
Senders S; Klein NP; Lamberth E; Thompson A; Drozd J; Trammel J; Peng Y; Giardina PC; Jansen KU; Gruber WC; Scott DA; Watson W
Pediatr Infect Dis J; 2021 Oct; 40(10):944-951. PubMed ID: 34525007
[TBL] [Abstract][Full Text] [Related]
27. A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age.
Chu K; Hu Y; Pan H; Wu J; Zhu D; Young MM; Luo L; Yi Z; Giardina PC; Gruber WC; Scott DA; Watson W
Hum Vaccin Immunother; 2023 Aug; 19(2):2235926. PubMed ID: 37549923
[No Abstract] [Full Text] [Related]
28. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan.
Togashi T; Okada K; Yamaji M; Thompson A; Gurtman A; Cutler M; Aizawa M; Gruber WC; Scott DA
Pediatr Infect Dis J; 2015 Oct; 34(10):1096-104. PubMed ID: 26121200
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India.
Amdekar YK; Lalwani SK; Bavdekar A; Balasubramanian S; Chhatwal J; Bhat SR; Verghese VP; Tansey SP; Gadgil D; Jiang Q; Pride M; Emini EA; Gruber WC; Scott DA
Pediatr Infect Dis J; 2013 May; 32(5):509-16. PubMed ID: 23190777
[TBL] [Abstract][Full Text] [Related]
31. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants.
Martinón-Torres F; Czajka H; Center KJ; Wysocki J; Majda-Stanislawska E; Omeñaca F; Bernaola Iturbe E; Blazquez Gamero D; Concheiro-Guisán A; Gimenez-Sanchez F; Szenborn L; Giardina PC; Patterson S; Gruber WC; Scott DA; Gurtman A
Pediatrics; 2015 Apr; 135(4):e876-86. PubMed ID: 25780077
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study.
Lalwani SK; Ramanan PV; Sapru A; Sundaram B; Shah BH; Kaul D; Karthik Nagesh N; Kalina WV; Chand R; Ding M; Suroju S; Scott DA; Lockhart SP
Vaccine; 2021 Nov; 39(46):6787-6795. PubMed ID: 34656378
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
[TBL] [Abstract][Full Text] [Related]
34. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
Martinon-Torres F; Wysocki J; Szenborn L; Carmona-Martinez A; Poder A; Dagan R; Richmond P; Gilbert C; Trudel MC; Flores S; Lupinacci R; McFetridge R; Wiedmann RT; Chen Q; Gerrits H; Banniettis N; Musey L; Bickham K; Kaminski J;
Vaccine; 2023 May; 41(21):3387-3398. PubMed ID: 37105892
[TBL] [Abstract][Full Text] [Related]
35. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial.
Thompson AR; Klein NP; Downey HJ; Patterson S; Sundaraiyer V; Watson W; Clarke K; Jansen KU; Sebastian S; Gruber WC; Scott DA; Schmöele-Thoma B
Hum Vaccin Immunother; 2019; 15(2):444-451. PubMed ID: 30303436
[TBL] [Abstract][Full Text] [Related]
36. Post hoc analysis of a randomized double-blind trial of the correlation of functional and binding antibody responses elicited by 13-valent and 7-valent pneumococcal conjugate vaccines and association with nasopharyngeal colonization.
Juergens C; Patterson S; Trammel J; Greenberg D; Givon-Lavi N; Cooper D; Gurtman A; Gruber WC; Scott DA; Dagan R
Clin Vaccine Immunol; 2014 Sep; 21(9):1277-81. PubMed ID: 24990907
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in China.
Chen JJ; Yuan L; Huang Z; Shi NM; Zhao YL; Xia SL; Li GH; Li RC; Li YP; Yang SY; Xia JL
BMJ Open; 2016 Oct; 6(10):e012488. PubMed ID: 27798013
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers.
Yeh SH; Gurtman A; Hurley DC; Block SL; Schwartz RH; Patterson S; Jansen KU; Love J; Gruber WC; Emini EA; Scott DA;
Pediatrics; 2010 Sep; 126(3):e493-505. PubMed ID: 20732948
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of 13-valent pneumococcal conjugate vaccine administered according to 4 different primary immunization schedules in infants: a randomized clinical trial.
Spijkerman J; Veenhoven RH; Wijmenga-Monsuur AJ; Elberse KE; van Gageldonk PG; Knol MJ; de Melker HE; Sanders EA; Schouls LM; Berbers GA
JAMA; 2013 Sep; 310(9):930-7. PubMed ID: 24002279
[TBL] [Abstract][Full Text] [Related]
40. 13-valent pneumococcal conjugate vaccine given with meningococcal C-tetanus toxoid conjugate and other routine pediatric vaccinations: immunogenicity and safety.
Martinón-Torres F; Gimenez-Sanchez F; Gurtman A; Bernaola E; Diez-Domingo J; Carmona A; Sidhu M; Sarkozy DA; Gruber WC; Emini EA; Scott DA;
Pediatr Infect Dis J; 2012 Apr; 31(4):392-9. PubMed ID: 22301472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
